Vesneo (latanoprostene bunod) filed with FDA for glaucoma or ocular hypertension- Bausch + Lomb
Bausch + Lomb has submitted a New Drug Application (NDA) to the FDA seeking approval for Vesneo (latanoprostene bunod ophthalmic solution 0.024%), an IOP lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. The data submitted in the NDA support VESNEO as the first nitric-oxide donating agent for ophthalmic use.
Positive top-line results from the pivotal Phase III studies conducted with Vesneo (latanoprostene bunod; previously known as BOL-303259-X and NCX 116) for the reduction of intraocular pressure (IOP) in patients with Glaucoma or Ocular Hypertension were announced in 2014.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)